GlobeNewswire

Infant Bacterial Therapeutics announces that the recruitment to the first stage of the Phase III Connection Study is completed - an update about the clinical development of IBP-9414

Share

Infant Bacterial Therapeutics (IBT) announces that the company has reached an important milestone after recruiting 300 premature infants to the ongoing clinical Phase III study of IBP-9414. This in part means that a safety analysis of these infants will take place in order to also recruit infants with a very low birth weight, which in turn is expected to significantly increase the recruitment rate. Furthermore it means that IBT has an opportunity to validate the study’s second primary endpoint, feeding tolerance, and redefine this if necessary.

IBTs clinical Phase III study of its drug candidate IBP-9414 for the prevention of necrotizing enterocolitis and improvement of feeding tolerance in premature infants, the Connection Study, started in July 2019. There are currently 68 neonatal intensive care units (NICUs) open for recruitment in the study. These NICUs are located in France, Hungary, Israel, Spain, the UK and the USA. The clinical trial application has further recently been approved in Bulgaria and Poland and submitted in Romania and Serbia. IBT expects that approximately 20 NICUs will open for recruitment in the coming months in these newly added countries. 

The majority of the infants intended to be recruited to the Connection Study will be extremely low birth weight (ELBW) premature infants, i.e they have birth weights of 1000 grams or below. These are the most vulnerable preterm infants and as a precautionary measure the study was designed to include 300 infants with birth weights between 750 and 1000 g in the first stage of the study. After the ongoing safety analysis of these infants the recruitment is intended to be broadened to include infants with a birthweight down to 500 g. This is expected to double the number of infants available for inclusion in the study and we anticipate a significant increase the speed of recruitment in the study. 

Prior to commencing the Connection Study, IBT agreed with the FDA to perform a pilot analysis of the first 300 patients with the purpose of qualitatively and quantitatively assessing the clinical meaning of the premature infants ability to, as soon as possible, receive enteral feeding without complication. Together with the external neonatology expert group we will analyze the correlation between sustained feeding tolerance and, for example, the incidence of sepsis in the infants. In accordance with the agreement with the FDA, the purpose of the pilot analysis is to validate the second primary endpoint of the study and if necessary redefine it.  

At the beginning of 2020 and prior to the COVID 19 pandemic, recruitment rates were close to those expected and IBT predicted reaching 300 patients during 2020. However, due to the effects of the pandemic, reaching this milestone has been delayed by a number of months. As previously communicated, IBT now anticipates to complete the study in 2022. 

Through extensive cooperation with the investigating NICUs, IBT has been able to mitigate the pandemics effects on recruitment, and patients have been recruited during the duration of the pandemic. All patients included in the Connection Study are in-hospital patients and therefore no formal outpatient visits are required. Due to this, hospital restrictions on visiting have not affected the Connection Study. Through for example the use of virtual study monitoring, it has also been possible to maintain study quality in relation to patient data capture.

The pandemic has however affected recruitment to the study in several ways. Firstly, certain hospitals stopped recruitment to all clinical research studies and new studies were not allowed to start as the relevant research staff were allocated other responsibilities. Further, the staff on duty in the NICUs have in some cases been transferred to COVID-related intensive care departments. In addition, neonatologists in the study as well as scientific journals are reporting a dramatic drop in the numbers of premature infants born into their NICUs during the pandemic. Recruitment rates are expected to significantly increase once the pandemic is under control.    

Clinical trial supply is functioning well and the IBP-9414 product is well-accepted by hospital pharmacies involved in the Phase III study. IBT is also pleased that the ongoing stability program for the physical product IBP-9414 is going according to plan. 

The cost estimates for the Connection Study performed prior study start correspond to the actual incurred expenses. As previously communicated, IBT estimates that it has sufficient capital to complete the Phase III Study. 

The pandemic has in various ways affected the possibility to recruit patients to the study, not least when a limited weight group interval range was chosen as a precautionary measure for the first 300 patients in the study. The first phase of the study is being evaluated at the same time that we can conclude that the study quality is sufficient and that the study can be completed with IBTs current capital. IBT expects that the recruitment rate will increase during 2021 due to the combination of lower impact from the COVID pandemic, continued opening and activation of new hospitals and the fact that the study is expected to include infants with a birth weight down to 500 grams. The medical need for preventive treatment for necrotising enterocolitis and to improve feeding tolerance in preterm infants remains very high.

About Infant Bacterial Therapeutics AB
Infant Bacterial Therapeutics AB (publ) is a pharmaceutical company with a product in clinical stage with a vision to develop drugs influencing the infant microbiome, and thereby prevent or treat rare diseases affecting infants.

IBT is currently developing the drug candidate IBP-9414, for the prevention of necrotizing enterocolitis (“NEC”) and improvement of feeding tolerance in premature infants. IBP-9414 contains the active substance Lactobacillus reuteri, which is a human bacterial strain naturally present in breast milk. The product portfolio also includes another project, IBP-1016, for the treatment of gastroschisis, a severe and rare disease affecting infants. By developing these drugs, IBT has the potential to fulfill unmet needs for diseases where there are currently no prevention or treatment therapies available.

Infant Bacterial Therapeutics AB (“IBT”) is a public company domiciled in Stockholm. The company’s class B-shares shares are listed on Nasdaq Stockholm, Mid-cap (IBT B).

For additional information please contact
Staffan Strömberg, CEO
Daniel Mackey, CFO
Infant Bacterial Therapeutics AB
Bryggargatan 10
111 21 Stockholm
Phone: +46 70 670 1226
info@ibtherapeutics.com
www.ibtherapeutics.com

Publication

This information is information that Infant Bacterial Therapeutics AB is obliged to make public pursuant to the EU Market Abuse Regulation and the Securities Markets Act. The information was submitted for publication, through the agency of the contact persons set out above, at 15:00 CET on February 10, 2021. 

Attachment


About GlobeNewswire

GlobeNewswire
GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://globenewswire.com

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire

Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire

PRFoods Ltd Swedish subsidiary landed major victory in court, increases fish farming capacity. PRFoods signes bridge financing agreement with major shareholder.8.3.2021 12:53:52 CETPress release

Överumans Fisk AB, fully owned subsidiary of PRFoods, was issued in 2020 additional licence in Gaskeloukti, Västerbotten county, Sweden. Licence gave right to use 2400 tons of feed which would give output of 2200 tons of fish. Licence was challenged by local residents and Överumans Fisk AB itself to gain additional feed tonnage. Land and Environmental Court issued a verdict not to accept the challenge by local residents. Överumans Fisk AB complaint was fully accepted and feed amount was increased to 3600 tons. Verdict is valid (it may be challenged in Supreme Court, but it will not stop the validity of the permit) and Överumans Fisk AB can utilize the new permit already in 2020 and the company has started already necessary investments for increased feed amount. Gaskeloukti site requires investments in the amount of 2,5 million euros. New permit will allow Överumans Fisk to increase from 2022 or 2023 its sales compared to last years by 3,5 times and depending on fish prices will give ad

Enento Group Plc’s Notice to the Annual General Meeting8.3.2021 12:00:00 CETPress release

ENENTO GROUP PLC, STOCK EXCHANGE RELEASE ON 8 MARCH 2021 AT 1.00 P.M. EET Enento Group Plc’s Notice to the Annual General Meeting Notice is given to the shareholders of Enento Group Plc ("Enento" or the "Company") to the Annual General Meeting to be held on Monday 29 March 2021 starting at 10:00 a.m. (EET) at Rantatie Business Park, Tutka & Plotteri Meeting Room (Hermannin rantatie 8, Main entrance: Verkkosaarenkatu 5, 00580 Helsinki, Finland). The Company’s Board of Directors has resolved on exceptional meeting procedures based on the temporary legislative act to limit the spread of the Covid-19 pandemic (677/2020), which entered into force on 3 October 2020. In order to ensure the health and safety of the shareholders, employees and other stakeholders of the Company, the Annual General Meeting will be organized without shareholders’ and their proxy representatives’ presence at the Annual General Meeting venue. Shareholders can participate in the Annual General Meeting and use their s

algoWatt will coordinate the GeTUP project for sustainable mobility as-a-service in urban areas8.3.2021 11:30:57 CETPress release

algoWatt will coordinate the GeTUP project for sustainable mobility as-a-service in urban areas Total funding of EUR 1 million for a low environmental impact, customised and accessible travel planning solutionThe company leads a partnership with Genoa's public transport operator, 5 SMEs and some research bodies algoWatt S.p.A. a GreenTech Solutions Company listed on the Italian Stock Exchange (MTA), will coordinate the GeTUP research project on sustainable mobility and MaaS (mobility as a service) solutions in the urban environment. The GeTUP project, worth a total of Euro 2 million, has received funding of Euro 1 million from the POR FESR 2014-2020 - Axis 1 - Action 1.2.4 - Poles of Research and Innovation of the Liguria Region, following approval by Finanziaria Ligure per lo Sviluppo Economico - FI.L.S.E. S.p.A., a technical entity that supports and assists the Liguria Region and other Ligurian territorial entities in the design, definition and implementation of policies and interven

Nexstim Abp:s företrädesemission av 6,6 miljoner euro8.3.2021 11:05:00 CETPressemelding

Företagsmeddelande, insiderinformation, Helsingfors den 8 mars 2021 kl. 12.05 (EET) Nexstim Abp:s företrädesemission av 6,6 miljoner euro FÅR EJ PUBLICERAS ELLER SPRIDAS DIREKT ELLER INDIREKT I FÖRENTA STATERNA, AUSTRALIEN, SYDAFRIKA , HONGKONG, JAPAN, CANADA, NYA ZEELAND, SINGAPORE ELLER NÅGON ANNAN STAT DÄR SPRIDNINGEN ELLER PUBLICERINGEN STRIDER MOT LAGEN Nexstim Abp (NXTMH:HEX, NXTMS:STO) (”Nexstim” eller ”bolag”) meddelar att med bemyndigande av bolagets extra bolagsstämma den 1 mars 2021, har styrelsen idag fattat beslut om en företrädesemission av cirka 6,6 miljoner euro ("emissionen”). Kort om emissionen Nexstim:s nyemission av cirka 6,6 miljoner euro där rätten att teckna högst 219 811 378 aktier ("emissionaktierna") ska med företrädesrätt tillkomma bolagets aktieägare.Varje aktieägare i Nexstim tilldelas en (1) företrädesrätt som kontoförda värdepapper ("teckningsrätt"), per varje aktie i respektive ägares innehav på avstämningsdagen för emissionen den 10 mars 2021 ("avstämni

Nexstim Plc’s subscription rights issue of MEUR 6.68.3.2021 11:05:00 CETPress release

Company announcement, inside information, Helsinki, 8 March 2021 at 12.05 PM (EET) Nexstim Plc’s subscription rights issue of MEUR 6.6 NOT TO BE PUBLISHED OR DISTRIBUTED DIRECTLY OR INDIRECTLY TO THE UNITED STATES OF AMERICA, AUSTRALIA, SOUTH AFRICA, HONG KONG, JAPAN, CANADA, NEW ZEALAND OR SINGAPORE OR TO ANY OTHER COUNTRY WHERE THE DISTRIBUTION OR PUBLICATION IS ILLEGAL. Nexstim Plc (NXTMH:HEX, NXTMS:STO) (”Nexstim” or ”Company”) announces, that pursuant to the authorisation granted by the Extraordinary General Meeting of the Company on 1 March 2021, the Board of Directors of the Company has today decided to arrange a subscription rights issue of approximately EUR 6.6 million (the “Offering”). Summary of the Offering Nexstim's EUR 6.6 million issue of a maximum of 219,811,378 new shares ("Offer Shares") is a subscription rights issue, in which current shareholders have a pre-emptive right.Each shareholder of Nexstim receives one (1) book-entry subscription right ("Subscription Right"

SEK CREDIT OPERATION ANNOUNCEMENT8.3.2021 10:30:00 CETPress release

Bid date, 2021-03-08Auction date2021-03-08Settlement date2021-03-08Maturity Date2021-06-07Term13 weeksInterest rateThe Riksbank´s applicable repo rateBid times11.00-11.30 (CET/CEST) on the Bid dateConfirmation of bids to e-maileol@riksbank.seOffered volumeUnlimitedThe lowest accepted bid volume50 million SEKMaximum number of bids1Allocation Time11.45 (CET/CEST) on the Bid date Stockholm, 2021-03-08 Bid date, 2021-03-08Auction date2021-03-08Settlement date2021-03-08Maturity Date2021-09-06Term26 weeksInterest rateThe Riksbank´s applicable repo rateBid times11.00-11.30 (CET/CEST) on the Bid dateConfirmation of bids to e-maileol@riksbank.seOffered volumeUnlimitedThe lowest accepted bid volume50 million SEKMaximum number of bids1Allocation Time11.45 (CET/CEST) on the Bid date Stockholm, 2021-03-08 This is a translation of the Swedish version published on www.riksbank.se. In the case of any inconsistency between the English translation and the Swedish language version, the Swedish language v

RESULT OF RIKSBANK REVERSED AUCTIONS TREASURY BILLS8.3.2021 10:07:00 CETPress release

Auction date2021-03-08LoanMAY 2021IsinSE0015504907Coupon, %0.00Maturity 2021-05-19Tendered volume, SEK mln500 +/- 250Offered volume, SEK mln1,500 Volume bought, SEK mln500 Number of bids4 Number of accepted bids2 Average yield, %-0.204Lowest accepted yield, %-0.206Highest yield, %-0.201Accepted at lowest yield, %100.00 Auction date2021-03-08LoanSEP 2021IsinSE0014808747Coupon, %00.000Maturity2021-09-15 Tendered volume, SEK mln500 +/- 250Offered volume, SEK mln1,500 Volume bought, SEK mln500 Number of bids4 Number of accepted bids2 Average yield, %-0.201Lowest accepted yield, %-0.202Highest yield, %-0.199Accepted at lowest yield, %100.00